Daniel G. Baker - 21 Mar 2025 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CUE	Stock Option (right to buy)	Award	$0	+100,000		$0.000000	100,000	21 Mar 2025	Common Stock	100,000	$0.9900	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.